MedTrace Logo

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

NCT01425294 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 231

Last updated 2017-12-05

No results posted yet for this study

Summary

This study is a post-authorisation study, committed to Center for Drug Evaluation (CDE) and China Food and Drug Administration (CFDA), in order to provide more effectiveness and safety data about Faslodex in real world clinical practice in China. The primary objective of this study was to evaluate the effectiveness of Faslodex 250mg monthly to treat post-menopausal women with oestrogen receptor-positive locally advanced or metastatic breast cancer, for disease relapse on or after adjuvant anti-oestrogen therapy or disease progression on therapy with an anti-oestrogen, in terms of progression-free survival (PFS), by collecting real world data according to Chinese physicians' clinical practice.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Binghe Xu, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2016-01-30
Completion
2016-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01425294 on ClinicalTrials.gov